Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 43 min ago
Peer-reviewedCC BY-NC-ND 4.0BMC Gastroenterology

Claims-defined hepatic steatosis compatible with MASLD and reproductive outcomes after the first observed embryo transfer: a Korean nationwide cohort study

6 affiliations
  1. 1Medical Big Data Research Center, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Republic of Korea
  2. 2Department of Physiology, School of Medicine, CHA University, Pocheon-si, Republic of Korea
  3. 3Center for Translational Medicine, Medical Center Research Institute, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea
  4. 4Digestive Disease Center, CHA Gangnam Medical Center, CHA University School of Medicine, Seoul, Republic of Korea
  5. 5Digestive Disease Center, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Republic of Korea
  6. 6Department of Clinical Pharmacology & Therapeutics, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Republic of Korea

Abstract

Background: Metabolic dysfunction–associated steatotic liver disease (MASLD) is increasingly prevalent among women of reproductive age; however, its association with reproductive outcomes after in vitro fertilization (IVF) remains insufficiently characterized in population-level data. We evaluated pre-index claims-defined hepatic steatosis compatible with MASLD as the primary exposure of interest in relation to first claims-identified pregnancy and time to first claims-identified live birth after the first observed embryo transfer (ET). Inflammatory bowel disease, irritable bowel syndrome, and autoimmune hepatobiliary disease were included as gastrointestinal and hepatic comparators.

Methods: We conducted a retrospective cohort study using Korean National Health Insurance Service claims data from 2017 to 2024. Among 601,664 women with an infertility diagnosis (ICD-10 N97), 122,134 underwent a first observed ET between 2019 and 2023 after predefined exclusions. Exposures were ascertained from pre-index claims using disease-specific ascertainment windows. The co-primary outcomes were first claims-identified pregnancy and time to first claims-identified live birth after the index ET. Claims-defined pregnancy loss was a secondary outcome among women with a first claims-identified pregnancy. Associations were analyzed using inverse probability of treatment weighting (IPTW)-adjusted Cox and logistic regression models, with false discovery rate (FDR) correction and E-value analyses.

Results: Among 122,134 women (mean age, 36.4 ± 4.2 years), 82.1% had a first claims-identified pregnancy and 62.7% had a claims-identified live birth during follow-up. After IPTW adjustment, claims-defined hepatic steatosis compatible with MASLD was associated with a modestly lower hazard of first claims-identified pregnancy (hazard ratio [HR] 0.93; 95% confidence interval [CI] 0.88–0.98; FDR q = 0.049) and first live birth during follow-up (HR 0.88; 95% CI 0.82–0.94; FDR q = 0.0006). It was not associated with claims-defined pregnancy loss among women with a first claims-identified pregnancy.

Conclusions: Pre-index claims-defined hepatic steatosis compatible with MASLD was associated with modestly lower hazards of first claims-identified pregnancy and first live birth during follow-up. Because body mass index, ovarian-reserve markers, clearly separated ovarian phenotypes, male-factor information, and cycle-level characteristics were unavailable, MASLD-compatible hepatic steatosis may represent a broader metabolic–reproductive phenotype rather than an independent hepatic effect. Given the modest E-values, these findings are hypothesis-generating and should not be interpreted causally or used alone to guide individual IVF counseling or treatment decisions.

Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s12876-026-05231-4.

Related

  1. Fatty liver index-defined hepatic steatosis and impaired fasting glucose differentially associate with incident diabetes and cardiovascular events in older adults: a nationwide cohort study
    Young Sang Lyu, Minae Park, Hee Kyung Kim +8
    Cardiovascular DiabetologyPeer-reviewedCC BY 4.0Full textGeneral medicinePMC
  2. Institutional Perspectives on Assisted Reproductive Technology Using Third‐Party Gametes in Japan: A Nationwide Survey of Assisted Reproductive Technology Facilities
    Nozomi Takahashi, Miyuki Harada, Hiroshi Koike +13
    Reproductive Medicine and BiologyPeer-reviewedCC BY 4.0Full textObstetrics, gynaecology & paediatricsPMC
  3. Long-term outcomes of ultrasound-detected hepatic steatosis in primary care: a record linkage study
    Richard J Lilford, Felicity Evison, Katharine Reeves +4
    BMJ OpenPeer-reviewedCC BY 4.0Full textGeneral medicineCrossrefPMC
  4. Silymarin-Based Therapies in Chronic Liver Disease: A Systematic Review of Biochemical, Cardiometabolic, Steatosis, and Fibrosis-Related Outcomes
    Hyo Young Lee, Hyunwoo Oh, Eileen Laurel Yoon +1
    NutrientsPeer-reviewedCC BY 4.0NutritionCrossref
  5. Rural-urban inequalities and determinants of period poverty among women of reproductive age in Nigeria: evidence from a nationwide study.
    Michael Mensah, Sampson Opoku, Obasanjo Bolarinwa +1
    International journal for equity in healthPeer-reviewedCC BY-NC-NDFull textEpidemiology & public healthEurope PMCPMC
BibTeX
@article{you2026claimsdefined,
  title = {{Claims-defined hepatic steatosis compatible with MASLD and reproductive outcomes after the first observed embryo transfer: a Korean nationwide cohort study}},
  author = {Seung-Hun You and Dong Hyeon Lee and Ah Young Lee and Kwanjoo Lee and Wonsuk Shin and Jun-young Seo},
  journal = {BMC Gastroenterology},
  year = {2026},
  month = aug,
  doi = {10.1186/s12876-026-05231-4},
  url = {https://doi.org/10.1186/s12876-026-05231-4},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Claims-defined hepatic steatosis compatible with MASLD and reproductive outcomes after the first observed embryo transfer: a Korean nationwide cohort study
AU  - Seung-Hun You
AU  - Dong Hyeon Lee
AU  - Ah Young Lee
AU  - Kwanjoo Lee
AU  - Wonsuk Shin
AU  - Jun-young Seo
PY  - 2026
DA  - 2026/08/15
JO  - BMC Gastroenterology
DO  - 10.1186/s12876-026-05231-4
UR  - https://doi.org/10.1186/s12876-026-05231-4
AB  - Background: Metabolic dysfunction–associated steatotic liver disease (MASLD) is increasingly prevalent among women of reproductive age; however, its association with reproductive outcomes after in vitro fertilization (IVF) remains insufficiently characterized in population-level data. We evaluated pre-index claims-defined hepatic steatosis compatible with MASLD as the primary exposure of interest in relation to first claims-identified pregnancy and time to first claims-identified live birth after the first observed embryo transfer (ET). Inflammatory bowel disease, irritable bowel syndrome, and autoimmune hepatobiliary disease were included as gastrointestinal and hepatic comparators.  Methods: We conducted a retrospective cohort study using Korean National Health Insurance Service claims data from 2017 to 2024. Among 601,664 women with an infertility diagnosis (ICD-10 N97), 122,134 underwent a first observed ET between 2019 and 2023 after predefined exclusions. Exposures were ascertained from pre-index claims using disease-specific ascertainment windows. The co-primary outcomes were first claims-identified pregnancy and time to first claims-identified live birth after the index ET. Claims-defined pregnancy loss was a secondary outcome among women with a first claims-identified pregnancy. Associations were analyzed using inverse probability of treatment weighting (IPTW)-adjusted Cox and logistic regression models, with false discovery rate (FDR) correction and E-value analyses.  Results: Among 122,134 women (mean age, 36.4 ± 4.2 years), 82.1% had a first claims-identified pregnancy and 62.7% had a claims-identified live birth during follow-up. After IPTW adjustment, claims-defined hepatic steatosis compatible with MASLD was associated with a modestly lower hazard of first claims-identified pregnancy (hazard ratio [HR] 0.93; 95% confidence interval [CI] 0.88–0.98; FDR q = 0.049) and first live birth during follow-up (HR 0.88; 95% CI 0.82–0.94; FDR q = 0.0006). It was not associated with claims-defined pregnancy loss among women with a first claims-identified pregnancy.  Conclusions: Pre-index claims-defined hepatic steatosis compatible with MASLD was associated with modestly lower hazards of first claims-identified pregnancy and first live birth during follow-up. Because body mass index, ovarian-reserve markers, clearly separated ovarian phenotypes, male-factor information, and cycle-level characteristics were unavailable, MASLD-compatible hepatic steatosis may represent a broader metabolic–reproductive phenotype rather than an independent hepatic effect. Given the modest E-values, these findings are hypothesis-generating and should not be interpreted causally or used alone to guide individual IVF counseling or treatment decisions.  Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s12876-026-05231-4.
SN  - 1471-230X
ER  -